Chiauranib Slows Platinum-Resistant Ovarian Cancer
The phase 3 CHIPRO trial has shown that the investigational drug chiauranib, when added to weekly paclitaxel, improves progression-free survival in patients with platinum-resistant ovarian cancer. The trial involved over 400 patients and demonstrated a significant extension in progression-free survival, although overall survival did not improve. Researchers noted the trial's relevance due to its inclusion of a substantial number of platinum-refractory patients.
- ▪The CHIPRO trial found that chiauranib extended progression-free survival to 4.6 months compared to 2.7 months with placebo.
- ▪The overall response rate was 32% in the chiauranib group versus 14.3% in the placebo group.
- ▪Treatment-emergent adverse events of grade 3 or worse affected 90% of patients receiving chiauranib.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/chiauranib-slows-platinum-resistant-ovarian-cancer-2026a1000iiv?src=rss |
| Publication time | Wed, 3 Jun 2026 08:35:50 EDT |
| Retrieval time | 2026-06-03T12:42:07.659Z |
| Last seen | 2026-06-03T12:42:07.659Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | _Aqi2cFiz_Tj |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Adding the investigational multi-kinase inhibitor chiauranib to weekly paclitaxel improves progression-free survival among patients with platinum-resistant or platinum-refractory ovarian cancer, according to findings from the phase 3 CHIPRO trial.The trial, involving over 400 patients in China, found that chiauranib extended progression-free survival to 4.6 months vs 2.7 months with weekly paclitaxel plus placebo. That translated to a 57% reduction in the risk for progression or death.Notably, about 10% of patients in the trial had platinum-refractory disease, and roughly 70% had previously received anti-angiogenic therapy.“CHIPRO is the first randomized study with a substantial primary platinum-refractory population, making it highly relevant to real-world practice,” researcher Xiaohua…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
